Recursion (RXRX) lost more than 4% in the early premarket trading on Thursday after a $200M equity offering from the AI-driven drug discovery firm overshadowed a decision by Sanofi (SNY) to select its ...

Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) snapped a three-day winning streak on Thursday, surging as much as 17.9 percent ...

The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...

Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically ...

Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.

Recursion, one of the most buzzed-about startups using machine learning to speed up drug discovery trials, said Wednesday it raised $239 million in Series D led by pharmaceutical maker Bayer.

Most patients (21 of 26; 80.8%) had TRAEs of Grade 2 or lower, consistent with MEK1/2 inhibition, including dermatitis acneiform, rash, CPK increase, diarrhea, and asymptomatic LVEF decrease. Grade 3 ...

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other ...

Recursion Pharmaceuticals (RXRX) held about $557 million in cash at the end of its second quarter of 2026. Investors should ...

RXRX's strategic partnerships are expanding its drug pipeline, strengthening AI capabilities and providing non-dilutive funding through early 2028.

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a digital biology™ company leading in the industrialization of drug discovery, today announced its acquisition of Vium, a digital vivarium™ company. Vium’s ...